title: Brentuximab vedotin (SGN-35) in a 3-year-old child with relapsed systemic anaplastic large cell lymphoma.
abstract: The treatment of anaplastic large cell lymphoma (ALCL) has largely relied on anthracycline-based chemotherapy. Targeted lymphoma therapy, using an anti-CD30 antibody, provides an innovative treatment modality for specific lymphomas, particularly ALCL. Brentuximab vedotin (BV; SGN-35) uses a CD30 monoclonal antibody to generate apoptosis of targeted lymphoma cells. We present a pediatric patient with ALCL who experienced second relapse after standard chemotherapy and autologous and allogeneic hematopoietic stem cell transplantation. This patient has been treated with BV as a single agent and has sustained remission for several months. BV offers a targeted treatment for relapsed ALCL, even after multiple relapses.
authors.affiliation: *Division of Pediatric Hematology/Oncology, Naval Medical Center Portsmouth, Portsmouth, VA Departments of †Pediatric Oncology/Blood and Marrow Transplant ‡Pathology, Columbia University Medical Center, NY Presbyterian Hospital, New York, NY.
authors.forename: Bethany
authors.initials: B
authors.lastname: Mikles
authors.forename: Jennifer
authors.initials: J
authors.lastname: Levine
authors.forename: Tatyana
authors.initials: T
authors.lastname: Gindin
authors.forename: Govind
authors.initials: G
authors.lastname: Bhagat
authors.forename: Prakash
authors.initials: P
authors.lastname: Satwani
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D002675:Child, Preschool; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D000922:Immunotoxins / Q000627:therapeutic use*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D016879:Salvage Therapy / Q000379:methods
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D000922:Immunotoxins; D000079963:Brentuximab Vedotin